Baxter announces major expansion in Germany

DEERFIELD - Baxter International Inc. said it will spend $100 million to expand its sterile drug injection manufacturing facility in Halle/Westfalen, Germany.

This facility is operated by BioPharma Solutions, a business unit of Baxter that specializes in partnering with pharmaceutical and biotech companies on the development and contract manufacturing of injection drug products.

"Baxter's manufacturing site in Halle/Westfalen is one of the most advanced facilities in our global network and has seen significant growth over the last several years," said Marie Keeley, general manager, Baxter BioPharma Solutions. "By making this investment, we are building on recent expansions to help ensure this facility can serve our partners at the highest level now and well into the future."

The investment will add state-of-the-art equipment designed to help products achieve stability and improved shelf life through freeze drying, or lyophilization, Baxter said. Construction will also add an aseptic syringe filling line, enabling BPS to meet the growing demand for this delivery platform in both Europe and the United States.